Conbercept
From PeptidePlaza, the free peptide reference · Entry #1191 · Metabolic · Sources fetched 2026-09-11 · Editorial standards
Conbercept is a metabolic research peptide. Conbercept is a vascular endothelial growth factor (VEGF) inhibitor, primarily studied for ophthalmic conditions.
Conbercept is a recombinant fusion protein that acts as an inhibitor of vascular endothelial growth factor A, B, and C, as well as placenta growth factor. It is currently in Phase 3 clinical trials for several indications, including macular degeneration and degenerative myopia. Research also explores its potential in retinal vein occlusion, wet macular degeneration, retinoblastoma, and corneal neovascularization. Studies frequently compare Conbercept with other anti-VEGF agents in the treatment of various retinal conditions.
1 Mechanism of action
Vascular endothelial growth factor A inhibitor (inhibitor); Vascular endothelial growth factor B inhibitor (inhibitor); Placenta growth factor inhibitor (inhibitor); Vascular endothelial growth factor C inhibitor (inhibitor)
2 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
2.1 Indicated / studied for
- Macular Degeneration
- Myopia, Degenerative
- Retinal Vein Occlusion
- Wet Macular Degeneration
- Retinoblastoma
- Corneal Neovascularization
3 Chemical and physical properties
| Purity (typical) | Not independently verified |
|---|---|
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
4 Research studies (8)
- Conbercept
(2006) · Review - Cost-effectiveness analysis of myopia management: A systematic review
Frontiers in public health (2023) · Systematic Review - Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis
The Cochrane database of systematic reviews (2023) · Systematic Review - Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis
Survey of ophthalmology (2024) · Systematic Review - New Anti-VEGF Drugs in Ophthalmology
Current drug targets (2020) · Review - Association Between Anti-vascular Endothelial Growth Factor Therapy Exposure and Visual Outcomes in Diabetic Macular Edema and Retinal Vein Occlusion
Journal of visualized experiments : JoVE (2026) - Efficacy and safety of conbercept, ranibizumab and laser in retinopathy of prematurity: A systematic review and network meta-analysis
Survey of ophthalmology (2026) · Systematic Review - Development and validation of a deep learning model to predict visual and anatomical prognosis of anti-VEGF therapy for neovascular age-related macular degeneration (KongMing Study): a prospective, nationwide, multicentre study
The Lancet. Digital health (2026)
5 Safety and risk profile
5.1 Regulatory status
Conbercept is currently classified as Phase 3 clinical trials. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.
6 Frequently asked questions
- What is Conbercept?
- Conbercept is a recombinant fusion protein that functions as an inhibitor of vascular endothelial growth factor A, B, and C, and placenta growth factor. It is being developed for the treatment of various eye conditions.
- How does Conbercept work?
- Conbercept works by inhibiting vascular endothelial growth factor (VEGF) A, B, and C, as well as placenta growth factor. By blocking these factors, it aims to reduce abnormal blood vessel growth and leakage, which are common in several ophthalmic diseases.
- What is Conbercept used for?
- Conbercept is being studied for the treatment of several eye conditions, including macular degeneration, degenerative myopia, retinal vein occlusion, wet macular degeneration, retinoblastoma, and corneal neovascularization.
- What is the regulatory status of Conbercept?
- Conbercept is currently in Phase 3 clinical trials for indications such as macular degeneration and degenerative myopia, indicating it is in advanced stages of development.
7 References
- Conbercept — molecule record ChEMBL. View source
- Conbercept — published literature (439 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Conbercept.
Shares vascular and endothelial pharmacology
Telbermin is a vascular endothelial growth factor receptor 1 and 2 (Flt-1 and KDR) agonist currently in Phase 2 clinical trials.
Shares growth and factor pharmacology
Becaplermin is a recombinant human platelet-derived growth factor, functioning as a platelet-derived growth factor receptor agonist. It is FDA-approved for the treatment of lower extremity diabetic neuropathic ulcers.
Also metabolic
A 16-amino acid peptide encoded within the mitochondrial genome — a newly discovered class of signaling molecule. Regulates metabolic homeostasis via AMPK and FOXO1 pathways.
Shares growth and factor pharmacology
Trafermin is an FDA-approved fibroblast growth factor receptor 2 agonist. It is studied for its role in tissue repair and regeneration.
Shares growth and factor pharmacology
An angiotensin IV derivative reported to be orders of magnitude more potent than BDNF at driving synaptogenesis. Its mechanism runs through c-Met — the same receptor that drives many cancers.
Also metabolic
A modified C-terminal fragment of human growth hormone (amino acids 177-191) with a tyrosine substitution. Studied primarily for its lipolytic (fat-burning) effects without the growth-promoting activity of full-length hGH.